VERACYTE, INC. (VCYT)
VERACYTE, INC. (VCYT) from its SEC filings: 2025 revenue $517.1 million (+16% vs the year before), net margin 13%, free cash flow $126.6 million. Insider trades, recent filings and a price chart. Free.
| Exchange | Nasdaq |
| Industry | Services-Medical Laboratories |
| Revenue (2025) | $517.1 million |
| Revenue growth | +16% |
| Net income | $66.4 million |
| Net margin | 12.8% |
| Free cash flow | $126.6 million |
| Diluted EPS | $0.82 |
| Latest quarter (Q2 2026 (calendar)) revenue vs a year earlier | +16% |
| Cash | $299.5 million |
| Long-term debt | $0 |
| Share count, 1 year | +2% |
| Fundamentals check | Strong fundamentals |
Source: SEC EDGAR company filings (XBRL), updated 2026-10-23. Education only, not financial advice.